JP2012522756A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522756A5 JP2012522756A5 JP2012502710A JP2012502710A JP2012522756A5 JP 2012522756 A5 JP2012522756 A5 JP 2012522756A5 JP 2012502710 A JP2012502710 A JP 2012502710A JP 2012502710 A JP2012502710 A JP 2012502710A JP 2012522756 A5 JP2012522756 A5 JP 2012522756A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- lif
- inhibitor
- gene
- glioma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 19
- 239000003112 inhibitor Substances 0.000 claims 17
- 238000000034 method Methods 0.000 claims 16
- 208000032612 Glial tumor Diseases 0.000 claims 10
- 206010018338 Glioma Diseases 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 4
- 108020004635 Complementary DNA Proteins 0.000 claims 3
- 230000004163 JAK-STAT signaling pathway Effects 0.000 claims 3
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims 3
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 claims 3
- 238000010804 cDNA synthesis Methods 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000013068 control sample Substances 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- -1 antibodies Proteins 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000002991 immunohistochemical analysis Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200900928 | 2009-04-03 | ||
| ES200900928A ES2363358B1 (es) | 2009-04-03 | 2009-04-03 | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| PCT/EP2010/054499 WO2010115868A2 (en) | 2009-04-03 | 2010-04-06 | Therapeutic agents for the treatment of diseases associated with undesired cell proliferation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178986A Division JP2016040255A (ja) | 2009-04-03 | 2015-09-11 | 望ましくない細胞増殖と関連する疾患の治療のための治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522756A JP2012522756A (ja) | 2012-09-27 |
| JP2012522756A5 true JP2012522756A5 (cg-RX-API-DMAC7.html) | 2013-05-23 |
| JP6207836B2 JP6207836B2 (ja) | 2017-10-04 |
Family
ID=42342718
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502710A Active JP6207836B2 (ja) | 2009-04-03 | 2010-04-06 | 望ましくない細胞増殖と関連する疾患の治療のための治療剤 |
| JP2015178986A Pending JP2016040255A (ja) | 2009-04-03 | 2015-09-11 | 望ましくない細胞増殖と関連する疾患の治療のための治療剤 |
| JP2018152551A Pending JP2019006784A (ja) | 2009-04-03 | 2018-08-14 | 望ましくない細胞増殖と関連する疾患の治療のための治療剤 |
| JP2020016672A Pending JP2020090522A (ja) | 2009-04-03 | 2020-02-04 | 望ましくない細胞増殖と関連する疾患の治療のための治療剤 |
| JP2021186785A Active JP7197665B2 (ja) | 2009-04-03 | 2021-11-17 | 望ましくない細胞増殖と関連する疾患の治療のための治療剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178986A Pending JP2016040255A (ja) | 2009-04-03 | 2015-09-11 | 望ましくない細胞増殖と関連する疾患の治療のための治療剤 |
| JP2018152551A Pending JP2019006784A (ja) | 2009-04-03 | 2018-08-14 | 望ましくない細胞増殖と関連する疾患の治療のための治療剤 |
| JP2020016672A Pending JP2020090522A (ja) | 2009-04-03 | 2020-02-04 | 望ましくない細胞増殖と関連する疾患の治療のための治療剤 |
| JP2021186785A Active JP7197665B2 (ja) | 2009-04-03 | 2021-11-17 | 望ましくない細胞増殖と関連する疾患の治療のための治療剤 |
Country Status (24)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007010394A2 (en) * | 2005-07-19 | 2007-01-25 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps |
| EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| JP2015071566A (ja) * | 2013-10-03 | 2015-04-16 | 住友ベークライト株式会社 | Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物 |
| IN2014MU00815A (cg-RX-API-DMAC7.html) * | 2014-03-11 | 2015-09-25 | Godavari Biorefineries Ltd | |
| CN112494646A (zh) * | 2014-06-30 | 2021-03-16 | 阿尔托生物科学有限公司 | 基于il-15的分子及其方法和用途 |
| JP2017527582A (ja) * | 2014-09-10 | 2017-09-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法 |
| EP3067422B1 (en) * | 2015-03-13 | 2024-07-31 | Sabanci Üniversitesi | Ct-1 inhibitors |
| AU2016235298B2 (en) | 2015-03-23 | 2021-03-11 | Evestra, Inc. | Novel cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents |
| EP3173483A1 (en) | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| US10583191B2 (en) | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| EP3555132B1 (en) * | 2016-12-19 | 2023-11-15 | Medimmune Limited | Antibodies against lif and uses thereof |
| AU2019269131B2 (en) * | 2018-05-14 | 2024-02-22 | Fundació Privada Institució Catalana De Recerca I Estudis Avançats | Antibodies against LIF and dosage forms thereof |
| EP3807315A2 (en) * | 2018-06-18 | 2021-04-21 | MedImmune Limited | Methods for improving response to anti-lif antibody treatment in individuals with cancer |
| CA3103369A1 (en) * | 2018-06-18 | 2019-12-26 | Medimmune Limited | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
| WO2020056349A2 (en) * | 2018-09-13 | 2020-03-19 | Evestra, Inc. | Lif/lifr antagonist oncology and nonmalignant diseases |
| JP7501876B2 (ja) * | 2019-04-17 | 2024-06-18 | 国立大学法人広島大学 | Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤 |
| CN111020030A (zh) * | 2019-12-03 | 2020-04-17 | 中山大学 | 一种骨肉瘤干细胞标志物及其应用、试剂盒 |
| EP3988116A1 (en) * | 2020-10-23 | 2022-04-27 | Consejo Superior De Investigaciones Científicas (CSIC) | Methods and compositions for the treatment of hematologic malignancies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| AU632993B2 (en) | 1987-12-15 | 1993-01-21 | Gene Shears Pty. Limited | Ribozymes |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| GB9004890D0 (en) * | 1990-03-05 | 1990-05-02 | Heath John K | Leukaemia inhibitory factor |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| JPH05304986A (ja) * | 1992-04-28 | 1993-11-19 | Tosoh Corp | ｇｐ１３０蛋白質に対するモノクロ−ナル抗体 |
| WO1993023556A1 (en) * | 1992-05-08 | 1993-11-25 | Genentech, Inc. | Antibodies to leukemia inhibitory factor |
| GB9413316D0 (en) | 1994-07-01 | 1994-08-24 | Cancer Res Campaign Tech | Novel proteins |
| US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
| US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| ATE412433T1 (de) * | 1999-02-12 | 2008-11-15 | Scripps Research Inst | Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| WO2003085093A2 (en) | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| JP2006512924A (ja) * | 2002-08-15 | 2006-04-20 | ジェンザイム・コーポレーション | 脳内皮細胞発現パターン |
| US20060078533A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004067778A2 (en) * | 2003-01-28 | 2004-08-12 | University Of South Florida | Differentially expressed genes in large granular lymphocyte leukemia |
| WO2005030803A1 (en) * | 2003-09-29 | 2005-04-07 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules |
| CN101052717A (zh) | 2004-05-11 | 2007-10-10 | α基因株式会社 | 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法 |
| EP2321433A2 (en) * | 2008-08-29 | 2011-05-18 | F. Hoffmann-La Roche AG | Diagnostics and treatments for vegf-independent tumors |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
-
2009
- 2009-04-03 ES ES200900928A patent/ES2363358B1/es not_active Withdrawn - After Issue
-
2010
- 2010-04-06 CN CN201711070081.2A patent/CN107964043A/zh active Pending
- 2010-04-06 WO PCT/EP2010/054499 patent/WO2010115868A2/en not_active Ceased
- 2010-04-06 CN CN2010800246730A patent/CN102574918A/zh active Pending
- 2010-04-06 US US13/138,804 patent/US10100112B2/en active Active
- 2010-04-06 EA EA201101450A patent/EA201101450A1/ru unknown
- 2010-04-06 AU AU2010233791A patent/AU2010233791B2/en not_active Ceased
- 2010-04-06 PT PT161550090T patent/PT3045474T/pt unknown
- 2010-04-06 SG SG10202010568RA patent/SG10202010568RA/en unknown
- 2010-04-06 KR KR1020207017470A patent/KR102373754B1/ko active Active
- 2010-04-06 EP EP10713619A patent/EP2414394A2/en not_active Ceased
- 2010-04-06 PL PL16155009T patent/PL3045474T3/pl unknown
- 2010-04-06 KR KR1020117026088A patent/KR20120100703A/ko not_active Ceased
- 2010-04-06 CA CA2757680A patent/CA2757680C/en active Active
- 2010-04-06 DK DK16155009.0T patent/DK3045474T3/da active
- 2010-04-06 MX MX2011010425A patent/MX336903B/es active IP Right Grant
- 2010-04-06 LT LTEP16155009.0T patent/LT3045474T/lt unknown
- 2010-04-06 ES ES16155009T patent/ES2864639T3/es active Active
- 2010-04-06 SI SI201032059T patent/SI3045474T1/sl unknown
- 2010-04-06 JP JP2012502710A patent/JP6207836B2/ja active Active
- 2010-04-06 SM SM20210153T patent/SMT202100153T1/it unknown
- 2010-04-06 HU HUE16155009A patent/HUE054196T2/hu unknown
- 2010-04-06 SG SG2011071834A patent/SG175032A1/en unknown
- 2010-04-06 KR KR1020187018827A patent/KR20180079470A/ko not_active Ceased
- 2010-04-06 KR KR1020227007752A patent/KR20220035978A/ko not_active Ceased
- 2010-04-06 KR KR1020177030504A patent/KR20170121319A/ko not_active Ceased
- 2010-04-06 BR BRPI1015369-1A patent/BRPI1015369A2/pt not_active Application Discontinuation
- 2010-04-06 KR KR1020197022597A patent/KR20190093691A/ko not_active Ceased
- 2010-04-06 EP EP16155009.0A patent/EP3045474B1/en active Active
-
2011
- 2011-10-02 IL IL215467A patent/IL215467A/en active IP Right Grant
- 2011-10-03 ZA ZA2011/07215A patent/ZA201107215B/en unknown
-
2015
- 2015-09-11 JP JP2015178986A patent/JP2016040255A/ja active Pending
-
2018
- 2018-08-14 JP JP2018152551A patent/JP2019006784A/ja active Pending
- 2018-08-28 US US16/115,191 patent/US20190211095A1/en not_active Abandoned
-
2020
- 2020-02-04 JP JP2020016672A patent/JP2020090522A/ja active Pending
- 2020-08-24 US US17/001,530 patent/US11999782B2/en active Active
-
2021
- 2021-03-02 HR HRP20210352TT patent/HRP20210352T1/hr unknown
- 2021-03-18 CY CY20211100232T patent/CY1124148T1/el unknown
- 2021-11-17 JP JP2021186785A patent/JP7197665B2/ja active Active
-
2024
- 2024-05-01 US US18/652,603 patent/US20240400667A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522756A5 (cg-RX-API-DMAC7.html) | ||
| JP6946385B2 (ja) | 乳がん転移の診断、予後診断、および処置のための方法 | |
| CN105980576B (zh) | 用于源自乳腺癌的骨转移癌的预后和治疗的方法 | |
| EP2650682A1 (en) | Method for the prognosis and treatment of cancer metastasis | |
| ES2647762T3 (es) | Métodos de uso de un nuevo receptor de eritropoyetina protector de tejido (NEPOR) | |
| JP2018078911A5 (cg-RX-API-DMAC7.html) | ||
| JP2015521050A5 (cg-RX-API-DMAC7.html) | ||
| JP2016105731A5 (cg-RX-API-DMAC7.html) | ||
| WO2014072517A1 (en) | Methods and kits for the prognosis of colorectal cancer | |
| CN104995313A (zh) | 使用c-maf的前列腺癌转移的诊断、预后和治疗的方法 | |
| CN101946008A (zh) | 用于控制血管生成的方法 | |
| Simile et al. | Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease | |
| KR101925125B1 (ko) | Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 | |
| US20140296098A1 (en) | Diagnostic and Prognostic Markers for Cancer | |
| JP2008525479A5 (cg-RX-API-DMAC7.html) | ||
| WO2020082037A1 (en) | Methods for treating a subtype of small cell lung cancer | |
| JP6397765B2 (ja) | プロテアソーム阻害剤に応答するバイオマーカー | |
| AU2008222602B2 (en) | A target for breast cancer therapy and/or diagnosis | |
| WO2011129427A1 (ja) | 癌の診断剤および治療剤 | |
| Jaszczynska-Nowinka et al. | Expression of SDF-1 and CXCR4 transcript variants and CXCR7 in epithelial ovarian cancer | |
| AU2008357875A1 (en) | Interferon Epsilon (IFNE1) as a marker for targeted cancer therapy | |
| CN117129690A (zh) | Grhl1在her2-乳腺癌诊断及预后评估中的应用 | |
| CN111630185A (zh) | 包含pmvk作为活性成分的用于诊断耐放射癌症或预测放射疗法预后的生物标志物组合物 | |
| JP2018524614A (ja) | 個別化された癌治療のための方法 | |
| KR20170052454A (ko) | 소라페닙 민감성 예측용 바이오마커 조성물 |